Literature DB >> 11752166

Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.

Tokiko Watanabe1, Shinji Watanabe, Gabriele Neumann, Hiroshi Kida, Yoshihiro Kawaoka.   

Abstract

Despite the success of influenza virus vaccines in reducing severe illness, their efficacy is suboptimal. We describe here the immunogenicity and protective capacity of replication-incompetent influenza virus-like particles (VLPs) which were generated entirely from cDNAs and lacked either the entire NS gene (encoding both the NS1 and NS2 protein) or only the NS2 gene. In mammalian cells infected with NS gene-deficient VLPs, the nucleoprotein, but not other viral proteins including hemagglutinin (HA) and neuraminidase (NA), was detected. In contrast, cells infected with VLPs expressing NS1 but not NS2 (NS2 knockout) expressed multiple viral proteins, including HA and NA. When challenged with lethal doses of an antigenically homologous mouse-adapted influenza virus, 94% of mice vaccinated with the NS2-knockout VLPs survived, compared with less than 10% of those given the NS-deficient VLPs. These results demonstrate the potential of replication-incompetent NS2-knockout VLPs as novel influenza vaccines and perhaps also as vectors to express genes from entirely unrelated pathogens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752166      PMCID: PMC136812          DOI: 10.1128/jvi.76.2.767-773.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Plasmid-driven formation of influenza virus-like particles.

Authors:  G Neumann; T Watanabe; Y Kawaoka
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Characterization of influenza virus NS1 protein by using a novel helper-virus-free reverse genetic system.

Authors:  M Enami; K Enami
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Mapping of the two overlapping genes for polypeptides NS1 and NS2 on RNA segment 8 of influenza virus genome.

Authors:  R A Lamb; P W Choppin; R M Chanock; C J Lai
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

4.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Authors:  K M Edwards; W D Dupont; M K Westrich; W D Plummer; P S Palmer; P F Wright
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

5.  Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus.

Authors:  H Kida; L E Brown; R G Webster
Journal:  Virology       Date:  1982-10-15       Impact factor: 3.616

6.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

Authors:  R B DuBridge; P Tang; H C Hsia; P M Leong; J H Miller; M P Calos
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

7.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

8.  Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1.

Authors:  G Neumann; M T Hughes; Y Kawaoka
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

9.  Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector.

Authors:  I Strobel; M Krumbholz; A Menke; E Hoffmann; P R Dunbar; A Bender; G Hobom; A Steinkasserer; G Schuler; R Grassmann
Journal:  Hum Gene Ther       Date:  2000-11-01       Impact factor: 5.695

10.  Molecular and biological changes in the cold-adapted "master strain" A/AA/6/60 (H2N2) influenza virus.

Authors:  M L Herlocher; H F Maassab; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more
  25 in total

Review 1.  Influenza vaccines: present and future.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  A replication-incompetent PB2-knockout influenza A virus vaccine vector.

Authors:  Sylvia T Victor; Shinji Watanabe; Hiroaki Katsura; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions.

Authors:  Ken Fujii; Yutaka Fujii; Takeshi Noda; Yukiko Muramoto; Tokiko Watanabe; Ayato Takada; Hideo Goto; Taisuke Horimoto; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions.

Authors:  Yukiko Muramoto; Ayato Takada; Ken Fujii; Takeshi Noda; Kiyoko Iwatsuki-Horimoto; Shinji Watanabe; Taisuke Horimoto; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding.

Authors:  Anna K Overby; Vsevolod Popov; Etienne P A Neve; Ralf F Pettersson
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

6.  Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes.

Authors:  Tokiko Watanabe; Shinji Watanabe; Takeshi Noda; Yutaka Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  The Streptococcus pyogenes capsule is required for adhesion of bacteria to virus-infected alveolar epithelial cells and lethal bacterial-viral superinfection.

Authors:  Shigefumi Okamoto; Shigetada Kawabata; Yutaka Terao; Hideaki Fujitaka; Yoshinobu Okuno; Shigeyuki Hamada
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 8.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

9.  Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.

Authors:  A-S Bergot; A Durgeau; B Levacher; B M Colombo; J L Cohen; D Klatzmann
Journal:  Cancer Gene Ther       Date:  2010-05-14       Impact factor: 5.987

10.  Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.

Authors:  Kyoko Shinya; Yutaka Fujii; Hiroshi Ito; Toshihiro Ito; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.